Literature DB >> 9011475

Patterns of progression: unpredictability and risk of decompensated cirrhosis.

N C Tassopoulos1.   

Abstract

Hepatitis C virus (HCV) infection appears to have a slow but progressive evolution to chronic hepatitis and cirrhosis in a significant percentage of patients. Chronic hepatitis develops in 60-80% of patients. Worldwide prospective studies have shown that a further 20-30% of patients with chronic active hepatitis will develop cirrhosis regardless of the possible source of HCV infection. The percentage of cirrhotics is generally believed to increase progressively as the length of follow-up increases. In patients with chronic HCV, there also is high risk for the development of hepatocellular carcinoma. Factors influencing the rate of progression from chronic hepatitis to cirrhosis appear to include age at time of exposure, duration of infection, degree of liver damage at initial biopsy, immunological status, and possibly HCV genotype. The mean intervals between the time of initial infection and the diagnosis of chronic hepatitis, cirrhosis, and hepatocellular carcinoma have been estimated to be 10, 20, and 30 years, respectively. The progression of disease is variable and is not always orderly and sequential. Patients can progress from chronic persistent hepatitis or chronic active hepatitis directly to hepatocellular carcinoma without first developing cirrhosis, especially those with genotype 1b. In addition, cirrhosis does not appear to lead to clinically apparent hepatic failure in all patients. Because of the variability in the clinical presentation and clinical progression of chronic HCV, long-term follow-up studies may be necessary to fully assess the sequelae of chronic HCV infection. Most patients with chronic HCV have abnormal liver histology but can present as otherwise healthy individuals. In contrast, patients with chronic HCV who have normal hepatic chemistries can have substantial hepatocellular damage. Consequently, treatment at diagnosis offers the greatest likelihood of eliminating the virus and preventing progression to more severe liver disease.

Entities:  

Mesh:

Year:  1996        PMID: 9011475     DOI: 10.1007/bf02087875

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  37 in total

1.  Antibody to the hepatitis C virus in acute hepatitis and chronic liver diseases in Japan.

Authors:  K Nishioka; J Watanabe; S Furuta; E Tanaka; H Suzuki; S Iino; T Tsuji; M Yano; G Kuo; Q L Choo
Journal:  Liver       Date:  1991-04

2.  Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV).

Authors:  U Hopf; B Möller; D Küther; R Stemerowicz; H Lobeck; A Lüdtke-Handjery; E Walter; H E Blum; M Roggendorf; F Deinhardt
Journal:  J Hepatol       Date:  1990-01       Impact factor: 25.083

3.  Primary hepatocellular carcinoma after chronic non-A, non-B post-transfusion hepatitis.

Authors:  J H Gilliam; K R Geisinger; J E Richter
Journal:  Ann Intern Med       Date:  1984-12       Impact factor: 25.391

4.  Clinico-pathological study of acute non-A, non-B post-transfusion hepatitis: histological features of liver biopsies in acute phase.

Authors:  M Omata; S Iwama; M Sumida; Y Ito; K Okuda
Journal:  Liver       Date:  1981-09

5.  Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis.

Authors:  H J Alter; R H Purcell; J W Shih; J C Melpolder; M Houghton; Q L Choo; G Kuo
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

6.  Risk factors for hepatocellular carcinoma among patients with chronic liver disease.

Authors:  H Tsukuma; T Hiyama; S Tanaka; M Nakao; T Yabuuchi; T Kitamura; K Nakanishi; I Fujimoto; A Inoue; H Yamazaki
Journal:  N Engl J Med       Date:  1993-06-24       Impact factor: 91.245

7.  The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team.

Authors:  M J Alter; H S Margolis; K Krawczynski; F N Judson; A Mares; W J Alexander; P Y Hu; J K Miller; M A Gerber; R E Sampliner
Journal:  N Engl J Med       Date:  1992-12-31       Impact factor: 91.245

8.  Hepatocellular carcinoma after non-A, non-B posttransfusion hepatitis.

Authors:  K Kiyosawa; Y Akahane; A Nagata; S Furuta
Journal:  Am J Gastroenterol       Date:  1984-10       Impact factor: 10.864

9.  Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities.

Authors:  E Silini; F Bono; A Cividini; A Cerino; S Bruno; S Rossi; G Belloni; B Brugnetti; E Civardi; L Salvaneschi
Journal:  Hepatology       Date:  1995-02       Impact factor: 17.425

10.  Clinical outcomes after transfusion-associated hepatitis C.

Authors:  M J Tong; N S el-Farra; A R Reikes; R L Co
Journal:  N Engl J Med       Date:  1995-06-01       Impact factor: 91.245

View more
  1 in total

1.  Noninvasive monitoring of hepatic damage from hepatitis C virus infection.

Authors:  J Alavez-Ramírez; J L Fuentes-Allen; J López-Estrada
Journal:  Comput Math Methods Med       Date:  2011-02-06       Impact factor: 2.238

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.